Author:
Chai Jinyan,Su Mengxue,Zhang Ruiguo,Li Ning,Jia Yuanyuan,Zheng Wei,Tan Jian,Jia Qiang,Sun Huabing,Meng Zhaowei
Abstract
AbstractAnaplastic thyroid carcinoma (ATC) is a rare but highly aggressive thyroid cancer with poor prognosis. Killing cancer cells by inducing DNA damage or blockage of DNA repair is a promising strategy for chemotherapy. It is reported that aldehyde-reactive alkoxyamines can capture the AP sites, one of the most common DNA lesions, and inhibit apurinic/apyrimidinic endonuclease 1(APE1)-mediated base excision repair (BER), leading to cell death. Whether this strategy can be employed for ATC treatment is rarely investigated. The aim of this study is to exploit GSH-responsive AP site capture reagent (AP probe-net), which responses to the elevated glutathione (GSH) levels in the tumor micro-environment (TME), releasing reactive alkoxyamine to trap AP sites and block the APE1-mediated BER for targeted anti-tumor activity against ATC. In vitro experiments, including MTT andγ-H2AX assays, demonstrate their selective cytotoxicity towards ATC cells over normal thyroid cells. Flow cytometry analysis suggests that AP probe-net arrests the cell cycle in the G2/M phase and induces apoptosis. Western blotting (WB) results show that the expression of apoptotic protein increased with the increased concentration of AP probe-net. Further in vivo experiments reveal that the AP probe-net has a good therapeutic effect on subcutaneous tumors of the ATC cells. In conclusion, taking advantage of the elevated GSH in TME, our study affords a new strategy for targeted chemotherapy of ATC with high selectivity and reduced adverse effects.
Funder
Natural Science Foundation of Tianjin Municipality
National Natural Science Foundation of China
Tianjin Municipal Science and Technology Committee
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Lorimer C, Cheng L, Chandler R, Garcez K, Gill V, Graham K, et al. Dabrafenib and Trametinib Therapy for Advanced anaplastic thyroid Cancer - Real-World outcomes from UK centres. Clin Oncol (R Coll Radiol). 2023;35(1):e60–6.
2. Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJM, Gelderblom H, Roozen ICFM, Bos M, Corver WE, van Wezel T, et al. Everolimus in patients with Advanced Follicular-derived thyroid Cancer: results of a phase II clinical trial. J Clin Endocrinol Metab. 2017;102:698–707.
3. Greenberg MM. Abasic and oxidized abasic site reactivity in DNA: enzyme inhibition, cross-linking, and nucleosome catalyzed reactions. Acc Chem Res. 2014;47(2):646–55.
4. Ma W, Westmoreland JW, Gordenin DA, Resnick MA. Alkylation base damage is converted into repairable double-strand breaks and complex intermediates in G2 cells lacking AP endonuclease. PLoS Genet. 2011;7(4):e1002059.
5. Varela JG, Pierce LE, Guo X, Price NE, Johnson KM, Yang Z, et al. Interstrand cross-link formation involving reaction of a Mispaired Cytosine Residue with an abasic site in duplex DNA. Chem Res Toxicol. 2021;34(4):1124–32.